Mangoceuticals (MGRX) Total Non-Current Liabilities (2022 - 2026)

Mangoceuticals has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $236965.0 for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $236965.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $236965.0 (changed N/A YoY), and the FY2023 annual result was $64961.0, down 49.52% from the prior year.
• Total Non-Current Liabilities came in at $236965.0 for Q1 2026 at Mangoceuticals, up from $12167.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $236965.0 in Q1 2026 to a low of $12167.0 in Q3 2024.
• The 4-year median for Total Non-Current Liabilities is $81508.0 (2023), against an average of $90307.7.
• Across the five-year window, Total Non-Current Liabilities plunged 49.52% in 2023 and slumped 85.07% in 2024, its largest moves.
• Mangoceuticals' Total Non-Current Liabilities stood at $128680.0 in 2022, then slumped by 49.52% to $64961.0 in 2023, then plunged by 81.27% to $12167.0 in 2024, then surged by 1847.6% to $236965.0 in 2026.
• The last three Total Non-Current Liabilities figures came in at $236965.0 (Q1 2026), $12167.0 (Q3 2024), and $30117.0 (Q2 2024), per Business Quant data.